The Food and Drug Administration has given permission, based off small clinical trials that have given promising results, for a "large-scale, Phase 3 clinical trials of the drug." Phase 3 clinical trials are usually the last step before a drug becomes prescription ready.
The announcement has proven controversial, while people generally seem to be happy that this may provide help for those suffering PTSD, others worry that people may absue this drug.
The New York times notes that many, like Andrew Parrott, a psychologist at Swansea University in Wales, that are criticizing the announcement feel that" allowing doctors to administer the drug to treat a disorder could inadvertently lead to a wave of abuse similar to the current opioid crisis."
Current research on the drug indicates that it "causes the brain to release a flood of hormones and neurotransmitters that evoke feelings of trust, love and well-being, while also muting fear and negative emotional memories that can be overpowering in patients with post-traumatic stress disorder. Patients say the drug gave them heightened clarity and ability to address their problems." The results have proven thus far to help those with PTSD continue their lives.
MDMA for now looks to be continuing its way into becoming a prescription drug, and the results for now indicate that this drug may become legalized sooner than we predicted. There will always be a potential for abusing drugs, but with proper education to the general public, we can only hope that PTSD survivors can be provided with a drug that may help them continue their lives in peace.
More information about this announcement can be found on the New York Times.